The Sky Shop For Hope
$25 Digital Mystery Box
$25 Digital Mystery Box
Couldn't load pickup availability
Make giving back fun and meaningful. Our $25 Mystery Box delivers a monthly curated digital phone wallpaper—a fresh design created to inspire, uplift, and brighten your screen. Each purchase directly supports Sky Foundation, a nonprofit dedicated to pancreatic cancer awareness and research.
Perfect for those who want to give monthly in a fun, creative way. Think of it as your monthly mystery surprise—beautiful art for you, and hope for those battling pancreatic cancer.
Your impact: Every Mystery Box fuels Sky Foundation’s mission to shine a light on early detection and support groundbreaking research.
FAQ Section
Q: How will I receive my monthly wallpaper?
A: Each month, your curated wallpaper will be delivered straight to your email. You’ll get a high-resolution digital file that works on all smartphones.
Q: Can I cancel my subscription anytime?
A: Yes! You’re in control. You can pause or cancel your Mystery Box subscription at any time through your account settings—no hidden fees or commitments.
Q: How does my purchase support Sky Foundation?
A: Every $25 Mystery Box helps fund Sky Foundation, a nonprofit leading the fight against pancreatic cancer. Your subscription fuels awareness and critical research.
Share

Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...